Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Carbognin L, Pilotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, Giannarelli D, Bria E, Tortora G. Carbognin L, et al. Oncologist. 2016 Mar;21(3):283-91. doi: 10.1634/theoncologist.2015-0307. Epub 2016 Feb 10. Oncologist. 2016. PMID: 26865589 Free PMC article.
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival.
Carbognin L, Sperduti I, Ciccarese M, Fabi A, Petrucelli L, Vari S, Forcignanò RC, Nortilli R, Vicentini C, Pilotto S, Merler S, Zampiva I, Brunelli M, Manfrin E, Giannarelli D, Tortora G, Bria E. Carbognin L, et al. Breast. 2016 Oct;29:24-30. doi: 10.1016/j.breast.2016.06.021. Epub 2016 Jul 7. Breast. 2016. PMID: 27394675
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.
Carbognin L, Sperduti I, Fabi A, Dieci MV, Kadrija D, Griguolo G, Pilotto S, Guarneri V, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Caliò A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E. Carbognin L, et al. Breast. 2017 Oct;35:21-26. doi: 10.1016/j.breast.2017.06.005. Epub 2017 Jun 17. Breast. 2017. PMID: 28628772
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model.
Carbognin L, Simbolo M, Caliò A, Vicentini C, Delfino P, Sperduti I, Fassan M, Schettini F, Dieci MV, Griguolo G, Pilotto S, Fiorio E, Arpino G, Guarneri V, De Placido S, Conte P, Manfrin E, Brunelli M, Scambia G, Scarpa A, Tortora G, Bria E. Carbognin L, et al. Breast. 2020 Apr;50:56-63. doi: 10.1016/j.breast.2020.01.034. Epub 2020 Jan 27. Breast. 2020. PMID: 32028173 Free PMC article.
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study.
Trestini I, Sperduti I, Caldart A, Bonaiuto C, Fiorio E, Parolin V, Zambonin V, Zanelli S, Tregnago D, Avancini A, Cintoni M, Pilotto S, Mele MC, Gasbarrini A, Scambia G, Milella M, Tortora G, Bria E, Carbognin L. Trestini I, et al. Among authors: carbognin l. Breast. 2021 Dec;60:6-14. doi: 10.1016/j.breast.2021.08.008. Epub 2021 Aug 21. Breast. 2021. PMID: 34454324 Free PMC article.
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: carbognin l. NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2. NPJ Breast Cancer. 2023. PMID: 37684252 Free PMC article.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: carbognin l. NPJ Breast Cancer. 2023 Oct 30;9(1):89. doi: 10.1038/s41523-023-00596-1. NPJ Breast Cancer. 2023. PMID: 37903774 Free PMC article. No abstract available.
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E, Furlanetto J, Carbognin L, Brunelli M, Caliolo C, Nortilli R, Massari F, Pedron S, Manfrin E, Pellini F, Bonetti F, Sperduti I, Pollini GP, Scarpa A, Tortora G. Bria E, et al. Among authors: carbognin l. Clin Breast Cancer. 2015 Feb;15(1):16-23. doi: 10.1016/j.clbc.2014.05.004. Epub 2014 Jun 23. Clin Breast Cancer. 2015. PMID: 25034441
79 results